WO2001051513A3 - Sequences associees a une tumeur ovarienne - Google Patents

Sequences associees a une tumeur ovarienne Download PDF

Info

Publication number
WO2001051513A3
WO2001051513A3 PCT/US2001/001575 US0101575W WO0151513A3 WO 2001051513 A3 WO2001051513 A3 WO 2001051513A3 US 0101575 W US0101575 W US 0101575W WO 0151513 A3 WO0151513 A3 WO 0151513A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian tumor
protein
compositions
ovarian
cancer
Prior art date
Application number
PCT/US2001/001575
Other languages
English (en)
Other versions
WO2001051513A2 (fr
Inventor
Paul A Algate
Original Assignee
Corixa Corp
Paul A Algate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Paul A Algate filed Critical Corixa Corp
Priority to AU2001236470A priority Critical patent/AU2001236470A1/en
Publication of WO2001051513A2 publication Critical patent/WO2001051513A2/fr
Publication of WO2001051513A3 publication Critical patent/WO2001051513A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et des procédés pour la thérapie et le diagnostic du cancer, tel que le cancer de l'ovaire. Ces compositions peuvent comprendre une ou plusieurs protéines de tumeur ovarienne, des parties immunogènes de ces dernières ou des polynucléotides qui codent ces parties. Par ailleurs, une composition thérapeutique peut comprendre une cellule présentant un antigène qui exprime une protéine de tumeur ovarienne, ou un lymphocyte T qui est spécifique pour ces cellules exprimant cette protéine. Ces compositions peuvent être utilisées, par exemple, pour prévenir et traiter des maladies comme le cancer de l'ovaire. L'invention traite également de procédés diagnostiques qui se fondent sur la détection d'une protéine tumorale ovarienne, ou un ARNm codant cette protéine, dans un échantillon.
PCT/US2001/001575 2000-01-14 2001-01-16 Sequences associees a une tumeur ovarienne WO2001051513A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236470A AU2001236470A1 (en) 2000-01-14 2001-01-16 Ovarian tumor-associated sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17672200P 2000-01-14 2000-01-14
US60/176,722 2000-01-14

Publications (2)

Publication Number Publication Date
WO2001051513A2 WO2001051513A2 (fr) 2001-07-19
WO2001051513A3 true WO2001051513A3 (fr) 2002-03-21

Family

ID=22645567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001575 WO2001051513A2 (fr) 2000-01-14 2001-01-16 Sequences associees a une tumeur ovarienne

Country Status (2)

Country Link
AU (1) AU2001236470A1 (fr)
WO (1) WO2001051513A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268466A1 (en) * 2000-06-13 2001-12-24 Agensys, Inc. 55p4h4: gene expressed in various cancers
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
JP2006519582A (ja) * 2002-09-26 2006-08-31 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
SI2398902T1 (sl) 2009-02-20 2024-04-30 Astellas Pharma Inc. Postopki in sestavki za diagnosticiranje in zdravljenje raka
SG10201500975YA (en) 2009-11-11 2015-04-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
AU2012258087B2 (en) 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOOKMAN M A: "BIOLOGICAL THERAPY OF OVARIAN CANCER: CURRENT DIRECTIONS", SEMINARS IN ONCOLOGY, BETHESDA, MD, US, vol. 25, no. 3, June 1998 (1998-06-01), pages 381 - 396, XP000892403 *
DATABASE EMBL 10 January 1997 (1997-01-10), ISHERWOOD J: "Human DNA sequence from PAC 296K21 on chromosome X", XP002175586 *
DATABASE EMBL 12 December 1997 (1997-12-12), BIRD: "Homo sapiens DNA sequence fom PAC 884M20 on chromosome Xp11.21", XP002175585 *
FORD D ET AL: "THE GENETICS OF BREAST AND OVARIAN CANCER", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 72, 1995, pages 805 - 812, XP000942635, ISSN: 0007-0920 *
GILLESPIE A M ET AL: "MAGE, BAGE AND GAGE: TUMOUR ANTIGEN EXPRESSION IN BENIGN AND MALIGNANT OVARIAN TISSUE", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 78, no. 6, September 1998 (1998-09-01), pages 816 - 821, XP000892404, ISSN: 0007-0920 *
MIKI Y ET AL: "A STRONG CANDIDATE FOR THE BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE BRCA1", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 266, 7 October 1994 (1994-10-07), pages 66 - 71, XP000202410, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU2001236470A1 (en) 2001-07-24
WO2001051513A2 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
WO2001096388A3 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001025272A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2000004149A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001000828A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2002083070A3 (fr) Composes pour l'ummunotherapie et le diagnostic du cancer du colon et methodes d'utilisation associees
WO2001040269A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001034802A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2000060076A3 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
WO2001075171A3 (fr) Methodes, compositions et necessaires correspondants servant au depistage et a la surveillance du cancer du sein
WO2001079286A3 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
WO2000037643A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
WO2001092581A3 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2001073027A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2001049716A3 (fr) Composes pour l'immunotherapie et le diagnostic du cancer du colon et procedes d'utilisation
WO2001051513A3 (fr) Sequences associees a une tumeur ovarienne
WO2001057207A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2000078960A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001070976A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer des ovaires et de l'endometre
WO2001073031A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer de l'ovaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP